Breaking News, Trials & Filings

Ruconest Effective in HAE study

Santarus, Pharming present results at ACAAIASM

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Santarus and Pharming Group will present new data from an open-label extension of the Phase III trial of Ruconest (recombinant human C1 esterase inhibitor, or rhC1INH) at the 2013 American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Ruconest was administered for the treatment of 224 repeat acute angioedema attacks in 44 patients with hereditary angioedema (HAE) following initial treatment in the randomized controlled Phase III study. The median time in minutes to ons...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters